Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors Before and After Allogeneic transplantation

The use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in treating aggressive hematological malignancies has potential for graft versus tumor (GVT) effect on one hand, and risk of graft versus host disease (GVHD) on the other. Despite the use of intensive conditioning followed by allo-HSCT, primary disease relapse remains one of the leading causes of death 1, 2. A summary report published by the Center for International Blood and Marrow Transplant (CIBMTR) shows that patients who received transplants from matched unrelated donors (MUD) and HLA matched siblings (MRD) have relapse rates of 30% and 40% respectively.

Source: Biology of Blood and Marrow Transplantation - September 5, 2018 Category: Hematology Authors: Awais Ijaz, Ali Younas Khan, Saad Ullah Malik, Warda Faridi, Muhammad Asad Fraz, Muhammad Usman, Muhammad Junaid Tariq, Seren Durer, Ceren Durer, Atlantis Russ, Nadia Nunes Cavalcante Parr, Zeeshan Baig, FNU Sagar, Zeeshan Ali, Ali McBride, Faiz Anwer Tags: Rapid communication Source Type: research